5 assets in GATA2 Deficiency With Susceptibility To MDS/AML

Therapeutic assets addressing GATA2 Deficiency With Susceptibility To MDS/AML, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fludarabine GATA2 Deficiency With Susceptibility To MDS/AML	Fred Hutchinson Cancer Center	P2	B (57)
Tacrolimus GATA2 Deficiency With Susceptibility To MDS/AML	Fred Hutchinson Cancer Center	P2	B (57)
Treosulfan GATA2 Deficiency With Susceptibility To MDS/AML	Fred Hutchinson Cancer Center	P2	B (57)
Methotrexate GATA2 Deficiency With Susceptibility To MDS/AML	Fred Hutchinson Cancer Center	P2	CCC (55)
Lapine T-Lymphocyte Immune Globulin GATA2 Deficiency With Susceptibility To MDS/AML	Fred Hutchinson Cancer Center	P2	CCC (48)